Global Exosomes Market research
Global Exosomes Market research

Exosomes Comprehensive Study by Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Others), Downstream Analysis (Cell Surface Marker Analysis using Flow Cytometry, Protein analysis using Blotting & ELISA, RNA analysis with NGS & PCR, Proteomic analysis using Mass Spectrometry, Others), Isolation Methods (Ultracentrifugation, Immunocapture on beads, Precipitation, Filtration), Biomolecule Type (Non-coding RNAs, MRNA, Proteins /peptides, DNA fragments, Lipids) Players and Region - Global Market Outlook to 2024

Exosomes Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 16.8%  

May 2019 Edition 218 Pages 167 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study
A growing number of research grants and projects by various research organizations will help to boost global exosomes market in the forecasted period. Exosomes play a significant role in facilitating cell-to-cell communication in the cancer prognosis. It helps to suppress the immune function by inducing apoptosis of activated cytotoxic T cells, which allow tumor progression in the human body. Also, exosomes stimulate the angiogenesis and migration leading to metastasis. In Addition, it triggers apoptosis in anti-tumor immune cells through tumor necrosis factor pathways. Increasing occurrence of cancer, technological advancements in exosomes isolation and analytical procedures are the key drivers of global exosomes market.

The market study is being classified, by Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases and Others) and major geographies with country level break-up. According to AMA, the Global Exosomes market is expected to see growth rate of 16.8%

Fujifilm (Japan), Thermo Fisher Scientific, Inc. (United States), Danaher (United States), Lonza (Switzerland), Illumina, Inc. (United States), Qiagen (Germany), Takara Bio Company (Japan), Malvern Instruments Ltd. (United Kingdom), Miltenyi Biotec (Germany) and Aethlon Medical, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Exosome Diagnostics Inc. (United States), NanoSomix Inc. (United States) and System Biosciences Inc. (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Exosomes market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Exosomes market by Type, Application and Region.

On the basis of geography, the market of Exosomes has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Downstream Analysis, the sub-segment i.e. Cell Surface Marker Analysis using Flow Cytometry will boost the Exosomes market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Isolation Methods , the sub-segment i.e. Ultracentrifugation will boost the Exosomes market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Biomolecule Type, the sub-segment i.e. Non-coding RNAs will boost the Exosomes market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • High Global Prevalence of Cancer
  • Increasing Interest in Exosome-Based Procedures

Market Trend
  • Rising Expenditure for Life Science Research and Developments
  • Growing Number of Advanced Applications of Exosomes

Restraints
  • Dearth of Skilled Professionals

Opportunities
  • High Adoption in Untapped Emerging Countries
  • Huge Opportunity Due to Personalized Medicine

Challenges
  • Stringent Regulatory Necessities for the Approval As Well As Commercialization of Exosomes


Market Leaders and their expansionary development strategies
On 13th July 2018, Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics have launched of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum.

On 25th June 2018, Bio-Techne Corporation has acquired Exosome Diagnostics, Inc. the deal was established for 250 million dollars in cash plus contingent consideration of up to 325 million dollars due upon the achievement of certain future milestones.

Key Target Audience
Medical Institutes, Industry Association Related to Exosomes, Government Regulatory Bodies, Government and Private Research Organization and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Cancer
  • Neurodegenerative diseases
  • Cardiovascular diseases
  • Infectious diseases
  • Others
By Downstream Analysis
  • Cell Surface Marker Analysis using Flow Cytometry
  • Protein analysis using Blotting & ELISA
  • RNA analysis with NGS & PCR
  • Proteomic analysis using Mass Spectrometry
  • Others

By Isolation Methods
  • Ultracentrifugation
  • Immunocapture on beads
  • Precipitation
  • Filtration

By Biomolecule Type
  • Non-coding RNAs
  • MRNA
  • Proteins /peptides
  • DNA fragments
  • Lipids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Global Prevalence of Cancer
      • 3.2.2. Increasing Interest in Exosome-Based Procedures
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Necessities for the Approval As Well As Commercialization of Exosomes
    • 3.4. Market Trends
      • 3.4.1. Rising Expenditure for Life Science Research and Developments
      • 3.4.2. Growing Number of Advanced Applications of Exosomes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Exosomes, by Application, Downstream Analysis, Isolation Methods , Biomolecule Type and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Exosomes (Value)
      • 5.2.1. Global Exosomes by: Application (Value)
        • 5.2.1.1. Cancer
        • 5.2.1.2. Neurodegenerative diseases
        • 5.2.1.3. Cardiovascular diseases
        • 5.2.1.4. Infectious diseases
        • 5.2.1.5. Others
      • 5.2.2. Global Exosomes by: Downstream Analysis (Value)
        • 5.2.2.1. Cell Surface Marker Analysis using Flow Cytometry
        • 5.2.2.2. Protein analysis using Blotting & ELISA
        • 5.2.2.3. RNA analysis with NGS & PCR
        • 5.2.2.4. Proteomic analysis using Mass Spectrometry
        • 5.2.2.5. Others
      • 5.2.3. Global Exosomes by: Biomolecule Type (Value)
        • 5.2.3.1. Non-coding RNAs
        • 5.2.3.2. MRNA
        • 5.2.3.3. Proteins /peptides
        • 5.2.3.4. DNA fragments
        • 5.2.3.5. Lipids
      • 5.2.4. Global Exosomes Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Exosomes: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fujifilm (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Danaher (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lonza (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Illumina, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Qiagen (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takara Bio Company (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Malvern Instruments Ltd. (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Miltenyi Biotec (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aethlon Medical, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Exosomes Sale, by Application, Downstream Analysis, Isolation Methods , Biomolecule Type and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Exosomes (Value)
      • 7.2.1. Global Exosomes by: Application (Value)
        • 7.2.1.1. Cancer
        • 7.2.1.2. Neurodegenerative diseases
        • 7.2.1.3. Cardiovascular diseases
        • 7.2.1.4. Infectious diseases
        • 7.2.1.5. Others
      • 7.2.2. Global Exosomes by: Downstream Analysis (Value)
        • 7.2.2.1. Cell Surface Marker Analysis using Flow Cytometry
        • 7.2.2.2. Protein analysis using Blotting & ELISA
        • 7.2.2.3. RNA analysis with NGS & PCR
        • 7.2.2.4. Proteomic analysis using Mass Spectrometry
        • 7.2.2.5. Others
      • 7.2.3. Global Exosomes by: Biomolecule Type (Value)
        • 7.2.3.1. Non-coding RNAs
        • 7.2.3.2. MRNA
        • 7.2.3.3. Proteins /peptides
        • 7.2.3.4. DNA fragments
        • 7.2.3.5. Lipids
      • 7.2.4. Global Exosomes Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Exosomes: by Application(USD Million)
  • Table 2. Exosomes Cancer , by Region USD Million (2013-2018)
  • Table 3. Exosomes Neurodegenerative diseases , by Region USD Million (2013-2018)
  • Table 4. Exosomes Cardiovascular diseases , by Region USD Million (2013-2018)
  • Table 5. Exosomes Infectious diseases , by Region USD Million (2013-2018)
  • Table 6. Exosomes Others , by Region USD Million (2013-2018)
  • Table 7. Exosomes: by Downstream Analysis(USD Million)
  • Table 8. Exosomes Cell Surface Marker Analysis using Flow Cytometry , by Region USD Million (2013-2018)
  • Table 9. Exosomes Protein analysis using Blotting & ELISA , by Region USD Million (2013-2018)
  • Table 10. Exosomes RNA analysis with NGS & PCR , by Region USD Million (2013-2018)
  • Table 11. Exosomes Proteomic analysis using Mass Spectrometry , by Region USD Million (2013-2018)
  • Table 12. Exosomes Others , by Region USD Million (2013-2018)
  • Table 13. Exosomes: by Biomolecule Type(USD Million)
  • Table 14. Exosomes Non-coding RNAs , by Region USD Million (2013-2018)
  • Table 15. Exosomes MRNA , by Region USD Million (2013-2018)
  • Table 16. Exosomes Proteins /peptides , by Region USD Million (2013-2018)
  • Table 17. Exosomes DNA fragments , by Region USD Million (2013-2018)
  • Table 18. Exosomes Lipids , by Region USD Million (2013-2018)
  • Table 19. South America Exosomes, by Country USD Million (2013-2018)
  • Table 20. South America Exosomes, by Application USD Million (2013-2018)
  • Table 21. South America Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 22. South America Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 23. South America Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 24. Brazil Exosomes, by Application USD Million (2013-2018)
  • Table 25. Brazil Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 26. Brazil Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 27. Brazil Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 28. Argentina Exosomes, by Application USD Million (2013-2018)
  • Table 29. Argentina Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 30. Argentina Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 31. Argentina Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 32. Rest of South America Exosomes, by Application USD Million (2013-2018)
  • Table 33. Rest of South America Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 34. Rest of South America Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 35. Rest of South America Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 36. Asia Pacific Exosomes, by Country USD Million (2013-2018)
  • Table 37. Asia Pacific Exosomes, by Application USD Million (2013-2018)
  • Table 38. Asia Pacific Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 39. Asia Pacific Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 40. Asia Pacific Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 41. China Exosomes, by Application USD Million (2013-2018)
  • Table 42. China Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 43. China Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 44. China Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 45. Japan Exosomes, by Application USD Million (2013-2018)
  • Table 46. Japan Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 47. Japan Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 48. Japan Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 49. India Exosomes, by Application USD Million (2013-2018)
  • Table 50. India Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 51. India Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 52. India Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 53. South Korea Exosomes, by Application USD Million (2013-2018)
  • Table 54. South Korea Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 55. South Korea Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 56. South Korea Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 57. Taiwan Exosomes, by Application USD Million (2013-2018)
  • Table 58. Taiwan Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 59. Taiwan Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 60. Taiwan Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 61. Australia Exosomes, by Application USD Million (2013-2018)
  • Table 62. Australia Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 63. Australia Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 64. Australia Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Exosomes, by Application USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 69. Europe Exosomes, by Country USD Million (2013-2018)
  • Table 70. Europe Exosomes, by Application USD Million (2013-2018)
  • Table 71. Europe Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 72. Europe Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 73. Europe Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 74. Germany Exosomes, by Application USD Million (2013-2018)
  • Table 75. Germany Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 76. Germany Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 77. Germany Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 78. France Exosomes, by Application USD Million (2013-2018)
  • Table 79. France Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 80. France Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 81. France Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 82. Italy Exosomes, by Application USD Million (2013-2018)
  • Table 83. Italy Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 84. Italy Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 85. Italy Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 86. United Kingdom Exosomes, by Application USD Million (2013-2018)
  • Table 87. United Kingdom Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 88. United Kingdom Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 89. United Kingdom Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 90. Netherlands Exosomes, by Application USD Million (2013-2018)
  • Table 91. Netherlands Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 92. Netherlands Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 93. Netherlands Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 94. Rest of Europe Exosomes, by Application USD Million (2013-2018)
  • Table 95. Rest of Europe Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 96. Rest of Europe Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 97. Rest of Europe Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 98. MEA Exosomes, by Country USD Million (2013-2018)
  • Table 99. MEA Exosomes, by Application USD Million (2013-2018)
  • Table 100. MEA Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 101. MEA Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 102. MEA Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 103. Middle East Exosomes, by Application USD Million (2013-2018)
  • Table 104. Middle East Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 105. Middle East Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 106. Middle East Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 107. Africa Exosomes, by Application USD Million (2013-2018)
  • Table 108. Africa Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 109. Africa Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 110. Africa Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 111. North America Exosomes, by Country USD Million (2013-2018)
  • Table 112. North America Exosomes, by Application USD Million (2013-2018)
  • Table 113. North America Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 114. North America Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 115. North America Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 116. United States Exosomes, by Application USD Million (2013-2018)
  • Table 117. United States Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 118. United States Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 119. United States Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 120. Canada Exosomes, by Application USD Million (2013-2018)
  • Table 121. Canada Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 122. Canada Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 123. Canada Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 124. Mexico Exosomes, by Application USD Million (2013-2018)
  • Table 125. Mexico Exosomes, by Downstream Analysis USD Million (2013-2018)
  • Table 126. Mexico Exosomes, by Isolation Methods USD Million (2013-2018)
  • Table 127. Mexico Exosomes, by Biomolecule Type USD Million (2013-2018)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Exosomes: by Application(USD Million)
  • Table 139. Exosomes Cancer , by Region USD Million (2019-2024)
  • Table 140. Exosomes Neurodegenerative diseases , by Region USD Million (2019-2024)
  • Table 141. Exosomes Cardiovascular diseases , by Region USD Million (2019-2024)
  • Table 142. Exosomes Infectious diseases , by Region USD Million (2019-2024)
  • Table 143. Exosomes Others , by Region USD Million (2019-2024)
  • Table 144. Exosomes: by Downstream Analysis(USD Million)
  • Table 145. Exosomes Cell Surface Marker Analysis using Flow Cytometry , by Region USD Million (2019-2024)
  • Table 146. Exosomes Protein analysis using Blotting & ELISA , by Region USD Million (2019-2024)
  • Table 147. Exosomes RNA analysis with NGS & PCR , by Region USD Million (2019-2024)
  • Table 148. Exosomes Proteomic analysis using Mass Spectrometry , by Region USD Million (2019-2024)
  • Table 149. Exosomes Others , by Region USD Million (2019-2024)
  • Table 150. Exosomes: by Biomolecule Type(USD Million)
  • Table 151. Exosomes Non-coding RNAs , by Region USD Million (2019-2024)
  • Table 152. Exosomes MRNA , by Region USD Million (2019-2024)
  • Table 153. Exosomes Proteins /peptides , by Region USD Million (2019-2024)
  • Table 154. Exosomes DNA fragments , by Region USD Million (2019-2024)
  • Table 155. Exosomes Lipids , by Region USD Million (2019-2024)
  • Table 156. South America Exosomes, by Country USD Million (2019-2024)
  • Table 157. South America Exosomes, by Application USD Million (2019-2024)
  • Table 158. South America Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 159. South America Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 160. South America Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 161. Brazil Exosomes, by Application USD Million (2019-2024)
  • Table 162. Brazil Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 163. Brazil Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 164. Brazil Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 165. Argentina Exosomes, by Application USD Million (2019-2024)
  • Table 166. Argentina Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 167. Argentina Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 168. Argentina Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 169. Rest of South America Exosomes, by Application USD Million (2019-2024)
  • Table 170. Rest of South America Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 171. Rest of South America Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 172. Rest of South America Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 173. Asia Pacific Exosomes, by Country USD Million (2019-2024)
  • Table 174. Asia Pacific Exosomes, by Application USD Million (2019-2024)
  • Table 175. Asia Pacific Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 176. Asia Pacific Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 177. Asia Pacific Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 178. China Exosomes, by Application USD Million (2019-2024)
  • Table 179. China Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 180. China Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 181. China Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 182. Japan Exosomes, by Application USD Million (2019-2024)
  • Table 183. Japan Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 184. Japan Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 185. Japan Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 186. India Exosomes, by Application USD Million (2019-2024)
  • Table 187. India Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 188. India Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 189. India Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 190. South Korea Exosomes, by Application USD Million (2019-2024)
  • Table 191. South Korea Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 192. South Korea Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 193. South Korea Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 194. Taiwan Exosomes, by Application USD Million (2019-2024)
  • Table 195. Taiwan Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 196. Taiwan Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 197. Taiwan Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 198. Australia Exosomes, by Application USD Million (2019-2024)
  • Table 199. Australia Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 200. Australia Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 201. Australia Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 202. Rest of Asia-Pacific Exosomes, by Application USD Million (2019-2024)
  • Table 203. Rest of Asia-Pacific Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 204. Rest of Asia-Pacific Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 205. Rest of Asia-Pacific Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 206. Europe Exosomes, by Country USD Million (2019-2024)
  • Table 207. Europe Exosomes, by Application USD Million (2019-2024)
  • Table 208. Europe Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 209. Europe Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 210. Europe Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 211. Germany Exosomes, by Application USD Million (2019-2024)
  • Table 212. Germany Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 213. Germany Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 214. Germany Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 215. France Exosomes, by Application USD Million (2019-2024)
  • Table 216. France Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 217. France Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 218. France Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 219. Italy Exosomes, by Application USD Million (2019-2024)
  • Table 220. Italy Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 221. Italy Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 222. Italy Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 223. United Kingdom Exosomes, by Application USD Million (2019-2024)
  • Table 224. United Kingdom Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 225. United Kingdom Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 226. United Kingdom Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 227. Netherlands Exosomes, by Application USD Million (2019-2024)
  • Table 228. Netherlands Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 229. Netherlands Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 230. Netherlands Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 231. Rest of Europe Exosomes, by Application USD Million (2019-2024)
  • Table 232. Rest of Europe Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 233. Rest of Europe Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 234. Rest of Europe Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 235. MEA Exosomes, by Country USD Million (2019-2024)
  • Table 236. MEA Exosomes, by Application USD Million (2019-2024)
  • Table 237. MEA Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 238. MEA Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 239. MEA Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 240. Middle East Exosomes, by Application USD Million (2019-2024)
  • Table 241. Middle East Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 242. Middle East Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 243. Middle East Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 244. Africa Exosomes, by Application USD Million (2019-2024)
  • Table 245. Africa Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 246. Africa Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 247. Africa Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 248. North America Exosomes, by Country USD Million (2019-2024)
  • Table 249. North America Exosomes, by Application USD Million (2019-2024)
  • Table 250. North America Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 251. North America Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 252. North America Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 253. United States Exosomes, by Application USD Million (2019-2024)
  • Table 254. United States Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 255. United States Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 256. United States Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 257. Canada Exosomes, by Application USD Million (2019-2024)
  • Table 258. Canada Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 259. Canada Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 260. Canada Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 261. Mexico Exosomes, by Application USD Million (2019-2024)
  • Table 262. Mexico Exosomes, by Downstream Analysis USD Million (2019-2024)
  • Table 263. Mexico Exosomes, by Isolation Methods USD Million (2019-2024)
  • Table 264. Mexico Exosomes, by Biomolecule Type USD Million (2019-2024)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Exosomes: by Application USD Million (2013-2018)
  • Figure 5. Global Exosomes: by Downstream Analysis USD Million (2013-2018)
  • Figure 6. Global Exosomes: by Biomolecule Type USD Million (2013-2018)
  • Figure 7. South America Exosomes Share (%), by Country
  • Figure 8. Asia Pacific Exosomes Share (%), by Country
  • Figure 9. Europe Exosomes Share (%), by Country
  • Figure 10. MEA Exosomes Share (%), by Country
  • Figure 11. North America Exosomes Share (%), by Country
  • Figure 12. Global Exosomes share by Players 2018 (%)
  • Figure 13. Global Exosomes share by Players (Top 3) 2018(%)
  • Figure 14. Global Exosomes share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Fujifilm (Japan) Revenue, Net Income and Gross profit
  • Figure 17. Fujifilm (Japan) Revenue: by Geography 2018
  • Figure 18. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2018
  • Figure 20. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 21. Danaher (United States) Revenue: by Geography 2018
  • Figure 22. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Lonza (Switzerland) Revenue: by Geography 2018
  • Figure 24. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Illumina, Inc. (United States) Revenue: by Geography 2018
  • Figure 26. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Qiagen (Germany) Revenue: by Geography 2018
  • Figure 28. Takara Bio Company (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Takara Bio Company (Japan) Revenue: by Geography 2018
  • Figure 30. Malvern Instruments Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Malvern Instruments Ltd. (United Kingdom) Revenue: by Geography 2018
  • Figure 32. Miltenyi Biotec (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Miltenyi Biotec (Germany) Revenue: by Geography 2018
  • Figure 34. Aethlon Medical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Aethlon Medical, Inc. (United States) Revenue: by Geography 2018
  • Figure 36. Global Exosomes: by Application USD Million (2019-2024)
  • Figure 37. Global Exosomes: by Downstream Analysis USD Million (2019-2024)
  • Figure 38. Global Exosomes: by Biomolecule Type USD Million (2019-2024)
  • Figure 39. South America Exosomes Share (%), by Country
  • Figure 40. Asia Pacific Exosomes Share (%), by Country
  • Figure 41. Europe Exosomes Share (%), by Country
  • Figure 42. MEA Exosomes Share (%), by Country
  • Figure 43. North America Exosomes Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Fujifilm (Japan)
  • Thermo Fisher Scientific, Inc. (United States)
  • Danaher (United States)
  • Lonza (Switzerland)
  • Illumina, Inc. (United States)
  • Qiagen (Germany)
  • Takara Bio Company (Japan)
  • Malvern Instruments Ltd. (United Kingdom)
  • Miltenyi Biotec (Germany)
  • Aethlon Medical, Inc. (United States)
Additional players considered in the study are as follows:
Exosome Diagnostics Inc. (United States) , NanoSomix Inc. (United States) , System Biosciences Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation